<DOC>
	<DOC>NCT02534909</DOC>
	<brief_summary>To determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with PNH.</brief_summary>
	<brief_title>Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Male and female patients between the age of 1875 (inclusive), or 1865 (applicable in Czech Republic) with a diagnosis of PNH prior to screening A documented PNH clone size of â‰¥10% by RBCs and/or granulocytes Serum LDH levels at least 1.5fold above the upper limit of normal (ULN) at screening Negative pregnancy test for women of child bearing potential at screening Previous vaccination against Neisseria meningitidis is required at least 2 weeks prior to first dosing. Known or suspected hereditary complement deficiency History of recurrent meningitis, history of meningococcal meningitis despite vaccination Presence or suspicion (based on judgment of the investigator) of active bacterial infection within 2 weeks prior to first dose of LFG316, or recurrent bacterial infections Under active therapy with other agents interfering with the complement system Severe concurrent comorbidities that are a likely caused by underlying autoimmune diseases other than PNH Women of childbearing potential, unless they are using highly effective methods of contraception during dosing and for 50 days after the last dose of LFG316.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>